Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of K-312 in Healthy Subjects
NCT02676596Phase 1Completed
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of K-312 in hyperlipidemia (6 cohorts). Primary endpoints: Cholesteryl Ester Transfer Protein activity at Day 30 and Area under the plasma concentration at Day 21. Started Apr 2014; status: completed.
02
Drugs
K-312
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02676596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676596.